Abstract Search

ba0001op20 | Clinical | ECTS2013

Resolution of effects on bone turnover markers and bone mineral density after discontinuation of long-term bisphosphonate use

Benhamou Claude , De Villiers Tobias , Johnston C Conrad , Langdahl Bente , Saag Kenneth , Denker Andrew , Pong Annpey , McGinnis John P , Rosenberg Elizabeth , Santora Arthur

see PP448....

0 shares

ba0001pp448 | Osteoporosis: treatment | ECTS2013

Resolution of effects on bone turnover markers and bone mineral density after discontinuation of long-term bisphosphonate use

Benhamou Claude , De Villiers Tobias , Johnston C Conrad , Langdahl Bente , Saag Kenneth , Denker Andrew , Pong Annpey , McGinnis John P , Rosenberg Elizabeth , Santora Arthur

Relatively little is known about immediate consequences of continuing vs interrupting long-term bisphosphonate treatment. This report describes changes in bone turnover and BMD in a 1-year, dose-finding trial of the calcium-sensing receptor antagonist MK-5442 in postmenopausal, BP-treated women, randomized to continued alendronate 70 mg weekly, switch to placebo, or switch to MK-5442. Recruited women (n=526) had taken alendronate for ≥12 months and an oral BP fo...

0 shares

ba0005oc1.1 | Clinical trials and osteoporosis treatment | ECTS2016

Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT)

Saag Kenneth G , Alexandersen Peter , Benhamou Claude-Laurent , Gilchrist Nigel , Halse Johan , Michael Lewiecki E. , Lippuner Kurt , McClung Michael , Shiraki Masataka , DaSilva Carolyn A , Verbruggen Nadia , Scott Boyd B , Lombardi Antonio

Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the primary efficacy analysis of the Phase 3, Long-Term ODN Fracture Trial (LOFT; NCT00529373), ODN significantly reduced fracture risk compared with placebo in postmenopausal women with osteoporosis. Pre-specified subgroup analyses evaluated the efficacy of ODN in patient subgroups.Women aged ≥65 years, without baseline radiographic...

0 shares

ba0001oc1.1 | Osteoporosis epidemiology and long term treatment complications | ECTS2013

Disease-specific perception of fracture risk and incident fracture rates among postmenopausal women: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)

Gregson Celia , Dennison Elaine , Compston Juliet , Adami Silvano , Adachi Jonathan , Anderson Frederick , Boonen Steven , Chapurlat Roland , Diez-Perez Adolfo , Greenspan Susan , Hooven Frederick , Lacroix Andrea , Nieves Jeri , Netelenbos J Coen , Pfeilschifter Johannes , Rossini Maurizio , Roux Christian , Saag Kenneth , Silverman Stuart , Siris Ethel , Watts Nelson , Wyman Allison , Cooper Cyrus

Patients with improved health understanding have greater autonomy over, and motivation towards, health-related lifestyles. We compared self-perceived fracture risk and 3-year incident fracture rates in postmenopausal women for a range of co-morbid diseases using data from the Global Longitudinal study of Osteoporosis in Women (GLOW).GLOW is an international cohort study involving 723 physician practices across 10 countries in Europe, North America, Austr...

0 shares

Bone Abstracts

Resolution of effects on bone turnover markers and bone mineral density after discontinuation of long-term bisphosphonate use

Resolution of effects on bone turnover markers and bone mineral density after discontinuation of long-term bisphosphonate use

Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT)

Disease-specific perception of fracture risk and incident fracture rates among postmenopausal women: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)

BiosciAbstracts